NASDAQ:SURF Surface Oncology (SURF) Stock Price, News & Analysis → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Free SURF Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.01▼$1.0950-Day Range$0.88▼$1.0852-Week Range$0.56▼$1.43Volume1.51 million shsAverage Volume430,375 shsMarket Capitalization$65.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Surface Oncology alerts: Email Address Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. About Surface Oncology Stock (NASDAQ:SURF)Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc.Read More Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. SURF Stock News HeadlinesMarch 28, 2024 | msn.comUP’s Professor Zodwa Dlamini and Team SAMBAI secure $25M to tackle global cancer InequitiesMarch 27, 2024 | msn.comThe little-known bacteria behind the rising rates of cancer in under 40sMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 27, 2024 | msn.comNot brushing your teeth and the other causes of rising cancer in the under 40sMarch 27, 2024 | finance.yahoo.comLumicell Introduces Further Research and Insights in Fluorescence-Guided Surgery at the Society of Surgical Oncology (SSO) Annual MeetingMarch 27, 2024 | msn.com26 Anti-Aging Secrets That Could Add Years to Your LifeMarch 23, 2024 | msn.com2 High-Yield Dividend Stocks Near 52-Week Lows. Time to Buy the Dips?March 22, 2024 | msn.comHow to Manage Anxiety and Depression When You Have Kidney CancerMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 22, 2024 | msn.comLungVax vaccine uses DNA technology to prevent lung cancerMarch 21, 2024 | msn.comConcomitant pharmacotherapy overcomes immunotherapy challenges in aggressive blood cancerMarch 21, 2024 | msn.comConstruction underway on $410 million Health First hospital complex on Merritt IslandMarch 21, 2024 | bizjournals.comBoston Scientific CEO compensation jumps 11% in 2023March 21, 2024 | msn.comFlamingo at Greenville Zoo reunites with feathery friends after cancer treatment.March 20, 2024 | msn.comBioNTech Se (BNTX) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | bizjournals.comJohns Hopkins cancer treatment spinout launches with $150M, establishes D.C.-area hubMarch 20, 2024 | bizjournals.comSurface Oncology CEO Rob Ross returns, with new $150M-backed startupMarch 13, 2024 | finanznachrichten.deZai Lab Limited: Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid TumorsMarch 13, 2024 | msn.comEarly clinical trial results show 'dramatic and rapid' regression of glioblastoma after next generation CAR-T therapyMarch 13, 2024 | msn.comLiving drugs that reprogram patients’ immune cells show early promise against hard-to-treat brain tumorsMarch 8, 2024 | msn.comHow 'Nyad' Helped Me Survive CancerMarch 7, 2024 | msn.com10 menopause myths and why it’s not as bad as people sayMarch 4, 2024 | finance.yahoo.comBiomunex Signs Exclusive Licensing Agreement With Institut Curie to Develop MAIT Engagers, a New Class of Bispecific Antibodies in Immuno-oncologyMarch 3, 2024 | msn.comPietro Signorile, gynecologist: ‘Endometriosis is a disease that affects our whole society’February 28, 2024 | msn.comPromising Combination Therapy May Help Target Triple-Negative Breast CancerFebruary 28, 2024 | msn.comSensory nerves appear to drive head and neck cancer growthFebruary 27, 2024 | msn.com9 Symptoms of Breast Cancer That Aren’t Lumps Every Woman Should KnowSee More Headlines Receive SURF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surface Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:SURF CUSIPN/A CIK1718108 Webwww.surfaceoncology.com Phone(617) 714-4096FaxN/AEmployees35Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,590,000.00 Net MarginsN/A Pretax Margin-211.95% Return on Equity-107.81% Return on Assets-65.57% Debt Debt-to-Equity RatioN/A Current Ratio3.60 Quick Ratio3.60 Sales & Book Value Annual Sales$30 million Price / Sales2.17 Cash FlowN/A Price / Cash FlowN/A Book Value$0.81 per share Price / Book1.32Miscellaneous Outstanding Shares60,824,000Free Float53,525,000Market Cap$65.08 million OptionableNot Optionable Beta1.75 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMs. Lisa McGrathChief People OfficerMs. Shannon Rourke DevensSr. VP of Devel. OperationsKey CompetitorsLeap TherapeuticsNASDAQ:LPTXCidara TherapeuticsNASDAQ:CDTXInflaRxNASDAQ:IFRXRegulus TherapeuticsNASDAQ:RGLSCellectar BiosciencesNASDAQ:CLRBView All CompetitorsInsidersJessica FeesSold 9,434 sharesTotal: $8,867.96 ($0.94/share)Robert W RossSold 16,713 sharesTotal: $15,710.22 ($0.94/share)Chandra AdamsSold 3,901 sharesTotal: $3,666.94 ($0.94/share) SURF Stock Analysis - Frequently Asked Questions Should I buy or sell Surface Oncology stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SURF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SURF, but not buy additional shares or sell existing shares. View SURF analyst ratings or view top-rated stocks. How were Surface Oncology's earnings last quarter? Surface Oncology, Inc. (NASDAQ:SURF) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.40) by $0.04. The company earned $0.39 million during the quarter. What is Jeff Goater's approval rating as Surface Oncology's CEO? 5 employees have rated Surface Oncology Chief Executive Officer Jeff Goater on Glassdoor.com. Jeff Goater has an approval rating of 100% among the company's employees. This puts Jeff Goater in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Surface Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Surface Oncology investors own include Pfizer (PFE), CrowdStrike (CRWD), QUALCOMM (QCOM), Fastly (FSLY), Intel (INTC), Hello Group (MOMO), NVIDIA (NVDA), U.S. Xpress Enterprises (USX), Xilinx (XLNX) and Genocea Biosciences (GNCA). When did Surface Oncology IPO? Surface Oncology (SURF) raised $84 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI served as the underwriters for the IPO. This page (NASDAQ:SURF) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surface Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.